Online inquiry

IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8076MR)

This product GTTS-WQ8076MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Dermatomyositis, Nephritis, Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8076MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9798MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ14205MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ4546MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ3071MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ3884MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ5274MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ1932MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ2313MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN-1210
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.